Prosecution Insights
Prosecution Insights
10 pending office actions • 7 art units • 9 examiners • 0 of 10 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (30%) |
| §112 only | 1 (10%) |
| Double-patenting + other | 2 (20%) |
| Multi-statute (no §101) | 3 (30%) |
| No statute on record | 1 (10%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALSOMAIRY, SARAH ABDOALATIF | 2 | 59.4% | +26.5% |
| ALLEN, MARIANNE P | 1 | 60.2% | +18.2% |
| BORGEEST, CHRISTINA M | 1 | 55.4% | +21.4% |
| LU, CHENG | 1 | 53.7% | +66.2% |
| DUFFY, PATRICIA ANN | 1 | 52.7% | +34.2% |
| DAUNER, JOSEPH G | 1 | 56.8% | +35.6% |
| XIAO, YAN | 1 | 67.8% | +51.6% |
| DONOGHUE, BRITTNEY ERIN | 1 | 58.6% | +48.8% |
| JOHANSEN, PETER N. | 1 | 58.9% | +24.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18010970 | MARKERS FOR USE IN METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) | DAUNER, JOSEPH G | 9d overdue |
| 18039473 | MODULATING THE IMMUNE RESPONSE USING ANTI-CD30 ANTIBODY-DRUG CONJUGATES | LU, CHENG | 46d |
| 18182203 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | DUFFY, PATRICIA ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17762867 | Combination Anti-CD30 ADC, Anti-PD-1 and Chemotherapeutic for Treatment of Hematopoietic Cancers | ALSOMAIRY, SARAH ABDOALATIF | 72d overdue |
| 17926206 | METHODS OF TREATING HER2 POSITIVE CANCER WITH TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND AN OXALIPLATIN-BASED CHEMOTHERAPY | XIAO, YAN | 43d overdue |
| 18017905 | METHODS OF TREATING HER2 POSITIVE CANCER WITH TUCATINIB IN COMBINATION WITH TRASTUZUMAB, A TAXANE, AND A VEGFR-2 ANTAGONIST | ALSOMAIRY, SARAH ABDOALATIF | 30d overdue |
| 16589914 | Methods of Treating Peripheral T Cell Lymphoma Using Anti-CD30 Antibody Drug Conjugate Therapy | JOHANSEN, PETER N. | 17d overdue |
| 18010970 | MARKERS FOR USE IN METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) | DAUNER, JOSEPH G | 9d overdue |
| 18334680 | Glycan-Interacting Compounds and Methods of Use | BORGEEST, CHRISTINA M | 13d |
| 18039473 | MODULATING THE IMMUNE RESPONSE USING ANTI-CD30 ANTIBODY-DRUG CONJUGATES | LU, CHENG | 46d |
| 18018504 | ANTI-CD228 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | ALLEN, MARIANNE P | — |
| Art Unit | Apps |
|---|---|
| 1675 | 2 |
| 1642 | 2 |
| 1646 | 2 |
| 1647 | 1 |
| 1645 | 1 |
| 1682 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18018504 | ANTI-CD228 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | ALLEN, MARIANNE P | 1647 | §102§103§112DP | Non-Final OA | — | Pending | Sep 15, 2023 |
| 18334680 | Glycan-Interacting Compounds and Methods of Use | BORGEEST, CHRISTINA M | 1675 | §112Other | Non-Final OA | 13d | Pending | Jun 14, 2023 |
| 18039473 | MODULATING THE IMMUNE RESPONSE USING ANTI-CD30 ANTIBODY-DRUG CONJUGATES | LU, CHENG | 1642 | §103§112Other | Non-Final OA | 46d | Pending | May 30, 2023 |
| 18182203 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | DUFFY, PATRICIA ANN | 1645 | §102§112 | Non-Final OA | — | Pending | Mar 10, 2023 |
| 18017905 | METHODS OF TREATING HER2 POSITIVE CANCER WITH TUCATINIB IN COMBINATION WITH TRASTUZUMAB, A TAXANE, AND A VEGFR-2 ANTAGONIST | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §103 | Final Rejection | 30d overdue | Pending | Jan 25, 2023 |
| 18010970 | MARKERS FOR USE IN METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) | DAUNER, JOSEPH G | 1682 | §103§112 | Final Rejection | 9d overdue | Pending | Dec 16, 2022 |
| 17926206 | METHODS OF TREATING HER2 POSITIVE CANCER WITH TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND AN OXALIPLATIN-BASED CHEMOTHERAPY | XIAO, YAN | 1642 | §103 | Final Rejection | 43d overdue | Pending | Nov 18, 2022 |
| 17779068 | TREATMENT OF CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | DONOGHUE, BRITTNEY ERIN | 1675 | §102§103§112DP | Non-Final OA | — | Pending | May 23, 2022 |
| 17762867 | Combination Anti-CD30 ADC, Anti-PD-1 and Chemotherapeutic for Treatment of Hematopoietic Cancers | ALSOMAIRY, SARAH ABDOALATIF | 1646 | Other | Final Rejection | 72d overdue | Pending | Mar 23, 2022 |
| 16589914 | Methods of Treating Peripheral T Cell Lymphoma Using Anti-CD30 Antibody Drug Conjugate Therapy | JOHANSEN, PETER N. | 1644 | §103Other | Final Rejection | 17d overdue | Pending | Oct 01, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial